Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes ΔΨ(m)) loss, caspase-9 activity, and apoptosis in Jurkat cells

Experimental Cell Research

Volumn 258, Issue 1, 2000, Pages 223-235

  Gamen, Susana ^a   Anel, Alberto ^a   Pérez Galán, Patricia ^a   Lasierra, Pilar ^a   Johnson, Daniel ^b   Piñeiro, Andrés ^a   Naval, Javier ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspases; Doxorubicin; Leukemia; Mitochondria

Indexed keywords

CASPASE; CASPASE 2; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CASPASE X; CYCLOHEXIMIDE; DOXORUBICIN; LAMIN B; PHOSPHATIDYLSERINE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE STEADY POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS;

GLYCINE MAX;

EID: 0034631974     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2000.4924     Document Type: Article

References (70)

1. Gewitz D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57:1999;727-741.
2. Barry M. A., Behnke C. A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40:1990;2353-2362.
3. Skladanowski A., Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem. Pharmacol. 46:1993;375-382.
4. Zaleskis G., Berleth E., Verstovsek S., Ehrke M. J., Mihich E. Doxorubicin-induced DNA degradation in murine thymocytes. Mol. Pharmacol. 46:1994;901-908.
5. Hannun Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.
6. Bose R., Verheij M., Haimovitz-Friedman A., Scotto K., Fuks Z., Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell. 82:1995;405-414.
7. Jaffrézou J. P., Levade T., Bettaïeb A., Andrieu N., Bezombes C., Maestre N., Vermeersch S., Rousse A., Laurent G. Daunorubicin-induced apoptosis: Triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15:1996;2417-2424.
8. Dbaibo G. S., Perry D. K., Gamard C. J., Platt R., Poirier G. G., Obeid L. M., Hannun Y. A. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumour necrosis factor (TNF)-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J. Exp. Med. 185:1997;481-490.
9. Gamen S., Anel A., Piñeiro A., Naval J. Caspases are the main executioniers of Fas-mediated apoptosis, irrespective of the ceramide-signaling pathway. Cell Death Differ. 5:1998;241-249.
10. Hofmann K., Dixit V. M. Trends Biochem. Sci. 23:1998;374-377.
11. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis of leukemia cells. Nature Med. 2:1996;574-577.
12. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:1997;3823-3829.
13. Gamen S., Anel A., Lasierra P., Alava M. A., Martinez-Lorenzo M. J., Piñeiro A., Naval J. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett. 417:1997;360-364.
14. Eischen C. M., Kottke T. J., Martins L. M., Basi G. S., Tung J. S., Earnshaw W. C., Leibson P. J., Kaufmann S. H. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 90:1997;935-943.
15. Villunger A., Egle A., Kos M., Hartmann B. L., Geley S., Kofler R., Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57:1997;3331-3334.
16. Yeh W. C., de la Pompa J. L., McCurrach M. E., Shu H. B., Elia A. J., Shahinian A., Ng M., Wakeham A., Khoo W., Mitchell K., El-Deiry W. S., Lowe S. W., Goeddel D. V., Mak T. W. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 279:1998;1954-1958.
17. Ruiz-Ruiz M. C., López-Rivas A. p53-mediated upregulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells. Cell Death Differ. 6:1999;271-280.
18. Wesselborg S., Engels I. H., Rossman E., Los M., Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 93:1999;3053-3063.
19. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res. 57:1997;62-67.
20. Antoku K., Liu Z., Johnson D. E. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia. 11:1997;1665-1672.
21. Sun X. M., MacFarlane M., Zhuang J., Wolf B. B., Green D. R., Cohen G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem. 274:1999;5053-5060.
22. Dou Q. P., An B., Antoku K., Johnson D. E. Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J. Cell. Biochem. 64:1997;586-594.
23. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D., Abbot B. J., Mayo J. G., Shoemaker R. H., Boyd M. R. Sensibility of drug screening with panels of human tumor cell lines using microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
24. Anel A., Gamen S., Alava M. A., Schmitt-Verhulst A. M., Piñeiro A., Naval J. Role of oxidative damage and ICE-like proteases in Fas-based cytotoxicity exerted by effector T cells. Int. Immunol. 8:1996;1173-1183.
25. Martin S. J., Reutelingsperger C. P. M., McGahon A. J., Rader J. A., van Schie R. C. A. A., LaFace D. M., Green D. R. Early redistribution of plasma membrane phosphatydilserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182:1995;1545-1556.
26. Petit P. X., Lecoeur H., Zorn E., Dauguet C., Mignotte B., Gougeon M. L. Alterations in mitochondrial structure and function are early events of dexamethsone-induced thymocyte apoptosis. J. Cell Biol. 130:1995;157-167.
27. Nicholson D. W., Ali A., Thornberry N. A., Vaillancourt J. P., Ding C. K., Gallant M., Gareau Y., Griffin P. R., Labelle M., Lazebnik Y. A., Munday N. A., Raju S. M., Smulson M. E., Yamin T. T., Yu V. L., Miller D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37-43.
28. García-Calvo M., Peterson E. P., Leiting B., Ruel R., Nicholson D. W., Thornberry N. A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273:1998;32608-32613.
29. Medema J. P., Scaffidi C., Kischkel F. C., Shevchenko A., Mann M., Krammer P. H., Peter M. E. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16:1997;2794-2804.
30. Talanian R. V., Quinlan C., Trautz S., Hackett M. C., Mankovich J. A., Banach D., Ghayur T., Brady K. D., Wong W. W. Substrate specificity of caspase family proteases. J. Biol. Chem. 272:1997;9677-9682.
31. Thornberry N. A., Rano T. A., Peterson E. P., Rasper D. M., Timkey T., Garcia-Calvo M., Houtzager V. M., Nordstrom P. A., Roy S., Vaillancourt J. P., Chapman K. T., Nicholson D. W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272:1997;17907-17911.
32. Schotte P., Declercq W., Van Huffel S., Vandenabeele P., Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett. 442:1999;117-121.
33. Lazebnik Y. A., Takahashi A., Moir R. D., Goldman R. D., Poirier G. G., Kaufmann S. H., Earnshw W. C. Studies of the lamin protease reveal multiple parallel biochemical pathways during apoptotic execution. Proc. Natl. Acad. Sci. USA. 92:1995;9042-9046.
34. Martins L. M., Kottke T., Mesner P. W., Basi G. S., Sinha S., Frigon N., Tatar E., Tung J. S., Bryant K., Takahashi A., Svingen P. A., Madden B. J., McCormick D. J., Earnshaw W. C., Kaufmann S. H. Activation of multiple interleukin-1β converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis. J. Biol. Chem. 272:1997;7421-7430.
35. Muzio M., Chinnayian A. M., Kischkel F. C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J. D., Zhang M., Gentz R., Mann M., Krammer P. H., Peter M. E., Dixit V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817-827.
36. Srinivasula S., Ahmad M., Fernandes-Alnemri T., Alnemri E. S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell. 1:1998;949-957.
37. Slee E. A., Harte M. T., Kluck R. M., Wolf B. B., Casiano C. A., Newmeyer D. D., Wang H. G., Reed J. C., Nicholson D. W., Alnemri E. S., Green D. R., Martin S. J. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 144:1999;281-292.
38. Zamzami N., Marchetti P., Castedo M., Zanin C., Vayssière J. L., Petit P. X., Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181:1995;1661-1672.
39. Naito M., Nagashima K., Mashima T., Tsuruo T. Phosphatidylserine externalization is a downstream event of interleukin-1β-converting enzyme family protease activation during apoptosis. Blood. 89:1997;2060-2066.
40. Müller I., Jenner A., Bruchelt G., Niethammer D., Halliwell B. Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Commun. 230:1997;254-257.
41. Muller C., Chatelut E., Gualano V., De Forni M., Huguet F., Attal M., Canal P., Laurent G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: Comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol. 32:1993;379-384.
42. Speth P. A., Linssen P. C., Boezeman J. B., Wessels H. M., Haanen C. Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemother. Pharmacol. 20:1987;305-310.
43. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M. E. Apoptosis signaling by death receptors. Eur. J. Biochem. 254:1998;439-459.
44. Martínez-Lorenzo M. J., Gamen S., Etxeberria J., Lasierra P., Larrad L., Piñeiro A., Anel A., Naval J., Alava M. A. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemias. Int. J. Cancer. 75:1998;473-481.
45. Nicholson D. W., Thornberry N. A. Caspases: Killer proteases. Trends Biochem. Sci. 22:1997;299-306.
46. Srinivasula S. M., Ahmad M., Fernandes-Alnemri T., Litwack G., Alnemri E. S. Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. USA. 93:1996;14486-14491.
47. Hedge R., Srinivasula S. M., Ahmad M., Fernandes-Alnemri T., Alnemri E. S. Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J. Biol. Chem. 273:1998;7783-7786.
48. Thakkar N. S., Potten C. S. Abrogation of adriamycin toxicity in vivo by cycloheximide. Biochem. Pharmacol. 43:1992;1683-1691.
49. Furusawa S., Nakano S., Kosaka K., Takayanagi M., Takayanagi Y., Sasaki K. Inhibition of doxorubicin-induced cell death in vitro and in vivo by cycloheximide. Biol. Pharm. Bull. 18:1995;1367-1372.
50. Yamato K., Yamamoto M., Hirano Y., Tsuchida N. A human temperature-sensitive p53 mutant p53Val-138: Modulation of the cell cycle, viability and expression of p53-responsive genes. Oncogene. 11:1995;1-6.
51. Perkins C., Kim C. N., Bhalla K. N. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res. 58:1998;4561-4566.
52. Sun D. Y., Jiang S., Zheng L. M., Ojcius D. M., Young J. D. E. Separate metabolic pathways leading to DNA fragmentation and apoptotic chromatin condensation. J. Exp. Med. 179:1994;559-568.
53. McFarlane M., Cain K., Sun X. M., Alnemri E. S., Cohen G. M. Processing/activation of at least four interleukin-1β converting enzyme-like proteases occurs during the execution phase of apoptosis in human momocytic tumor cells. J. Cell Biol. 137:1997;469-479.
54. Fearnhead H. O., Rodriguez J., Govek E. E., Guo W., Kobayashi R., Hannon G., Lazebnik Y. A. Oncogene-dependent apoptosis is mediated by caspase-9. Proc. Natl. Acad. Sci. USA. 95:1998;13664-13669.
55. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K. J., Debatin K. M., Krammer P. H., Peter M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687.
56. Yang J., Liu X., Bhalla K., Kim C. N., Ibrado A. M., Cai J., Peng T. I., Jones D. P., Wang X. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science. 275:1997;1129-1132.
57. Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 275:1997;1132-1136.
58. Susin S. A., Lorenzo H. K., Zamzami N., Marzo I., Snow B. E., Brothers G. M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D. R., Aebersold R., Siderovski D. P., Penninger J. M., Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 397:1999;441-446.
59. Mancini M., Nicholson D. W., Roy S., Thornberry N. A., Peterson E. P., Casciola-Rosen L. A., Rosen A. The caspase-3 precursor has a cytosolic and mitochondrial distribution: Implications for apoptotic signaling. J. Cell Biol. 140:1998;1485-1495.
60. Susin S. A., Lorenzo H. K., Zamzami N., Marzo I., Brenner C., Larochette N., Prévost M. C., Alzari P. M., Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med. 189:1999;381-393.
61. Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemri E. S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates apoptotic protease cascade. Cell. 91:1997;479-489.
62. Zhivotovsky B., Orrenius S., Brustugun O. T., Doskeland S. O. Injected cytochrome c induces apoptosis. Nature. 391:1998;449-450.
63. Rossé T., Olivier R., Monney L., Rager M., Conus S., Fellay I., Jansen B., Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 391:1998;496-499.
64. Marzo I., Susin S. A., Petit P. X., Ravagnan L., Brenner C., Larochette N., Zamzami N., Kroemer G. Caspases disrupt mitochondrial barrier function. FEBS Lett. 427:1998;198-202.
65. Bossy-Wetzel E., Green D. R. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. J. Biol. Chem. 274:1999;17484-17490.
66. Pan G., Humke E. W., Dixit V. M. Activation of caspases triggered by cytochrome c in vitro. FEBS Lett. 426:1998;151-154.
67. Marzo I., Brenner C., Zamzami N., Susin S. A., Beutner G., Brdiczka D., Rémy R., Xie Z. H., Reed J. C., Kroemer G. The permeability transition pore complex: A target for apoptosis regulation by caspases and Bcl-2-related proteins. J. Exp. Med. 187:1998;1261-1271.
68. Kuida K., Haydar T. F., Kuan C. Y., Gu Y., Taya C., Karasuyama H., Su M. S. S., Rakic P., Flavell R. A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 94:1998;325-337.
69. Hakem R., Hakem A., Duncan G. S., Henderson J. T., Woo M., Soengas M. S., Elia A., de la Pompa J. L., Kagi D., Khoo W., Potter J., Yoshida W., Kaufman S. A., Lowe S. W., Penninger J. M., Mak T. W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 94:1998;339-352.
70. McCarthy N. J., Whyte M. K. B., Gilbert C. S., Evan G. I. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. J. Cell. Biol. 136:1997;215-227.